Immunohistochemical evaluation of a new epithelial antigen, BER-EP4 in ovarian cancer: a propos of 62 cases

Objective: To assess the immunohistochemical expression of BerEP4, a new epithelial antigen in ovarian cancer. Methods: We studied 62 cases of ovarian cancer in which BerEP4, CEA and CA-125 were investigated by an immunohistochemical method. We evaluated the correlations among immunohistochemical positivity and the grading, histotype and stage of disease. Results: BerEP4 was positive in 45 out of 62 cases (72.58%), CA-125 in 36 out of 62 cases (58.06%) and CEA in ten out of 62 cases (16.13%). BerEP4 was present both in serous and in mucinous tumors (80.96% vs 80.77%). CA-125 was mainly expressed in serous vs mucinous tumors (66.67% vs 57.69%). CEA was more prevalent in mucinous vs serous tumors. Ber-EP4 was mainly expressed in G1 (75%) and G2 (77.27%). CA-125 was more present in G1 and G3 (both 62.50%) than G2 (50%), whereas CEA showed positivity in G1: 12.50%, G2: 22.73% and G3: 12.50%. There were no differences among the three antigens studied with regard to clinical stage. Conclusions: In our study Ber-EP4 was positive in 45 out of 62 cases (72.58%) of primary epithelial ovarian cancers. The presence of this antigen seemed to be related to the histotype and grading but not to clinical stage.

Epithelial antigen; BerEP4; Ovarian cancer

[1] Taylor K.J., Schwartz P.E.: “Cancer screening in a high risk population: a clinical trial”. Ultrasound Med. Biol., 2001, 27, 461.

[2] Woolas R.P., Oram D.H., Jeyarajah A.R., Bast R.C., Jacobs I.J.: “Ovarian cancer identified through screening with serum markers but not by pelvic imaging”. Int. J. Gynecol. Cancer, 1999, 9, 497.

[3] Partridge E.E., Barnes M.N.: “Epithelial ovarian cancer: prevention, diagnosis and treatment”. C.A. Cancer J. Clin., 1999, 49, 297.

[4] Van Dalen A., Favier J., Baumgartner L., Hasholzner U., De Bruijn H., Dobbler D. et al.: “Serum levels of CA 125 and TPS during treatment of ovarian cancer”. Anticancer Res., 2000, 20, 5107.

[5] Zurawski V.R., Knapp R.C., Einhorn N., Kenemans P., Mortel R., Ohmi K. et al.: “An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma”. Gynecol. Oncol., 1988, 30, 7.

[6] Tuxen M.K., Soletormos G., Rustin G.J., Nelstrop A.E., Dombernowsky P.: “Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer”. Scand. J. Clin. Lab. Invest., 2000, 60, 713.

[7] Nyvang G.B., Mogensen O., Bichel P., Jakobsen A.: “Combined prognostic importance of CA 125, histopathologic grade and DNA-index in advanced ovarian cancer”. Eur. J. Gynaecol. Oncol., 2000, 21, 569.

[8] Runnebaum I.B., Stickeler E.: “Epidemiological and molecular aspects of ovarian cancer risk”. J. Cancer Res. Clin. Oncol., 2001, 127, 73.

[9] Morrow C.P., Curtin J.P. (eds.): “Surgery for ovarian neoplasia”. In: Gynecologic Cancer Surgery. New York, Churchill Livingstone, 1996, 627.

[10] Elit L.: “Familial ovarian cancer”. Can. Fam. Physician, 2001, 47, 778.

[11] Werness B.A., Eltabbakh G.H.: “Familial ovarian cancer and early ovarian cancer: biologic, pathologic and clinical features”. Int. J. Gynecol. Pathol., 2001, 20, 48.

[12] Gitsch G., Tabery U., Feigl W., Breitenecker G.: “The differential diagnosis of primary peritoneal papillary tumors”. Arch. Gynecol. Obstet., 1992, 251, 139.

[13] Baker P.M., Oliva E., Young R.H., Talerman A., Scully R.E.: “Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases”. Am. J. Surg. Pathol., 2001, 25, 557.

[14] Latza U., Niedobitek G., Schwarting R., Nekarda H., Stein H.: “Ber-EP4. New monoclonal antibody which distinguishes epithelia from mesothelia“. J. Clin. Pathol., 1990, 43, 213.

[15] Cherchi P.L., Bosincu L., Dessole S., Ruiu G.A., Cossu Rocca P., Capobianco G. et al: “Immunohistochemical expression of BerEP4, a new epithelial antigen, in endometrial carcinoma: correlation with clinical parameters”. Eur. J. Gynaecol. Oncol., 1999, 20, 393.

[16] Manjunath A.P., Pratapkumar, Sujatha K., Vani R.: “Comparison of three risk of malignancy indices in evaluation of pelvic masses”. Gynecol. Oncol., 2001, 81, 225.

[17] Davidson B., Risberg B., Kristensen G., Kvalheim G., Emilsen E., Bjamer A. et al.: “Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers”. Virchows Arch., 1999, 435, 43.

[18] Comin C.E., Saieva C., Messerini L: “h-Caldesomn, Calretinin, Estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary”. Am. J. Pathol., 2007, 31, 1139.

[19] Okamoto S., Ito K., Sasano H., Moriya T., Niikura H., Terada Y.: “Ber-EP4 and anti -calretinin antibodies: a useful combination for differentiating diagnosis of various histological types of ovarian cancer cells and mesothelial cells”. Tohoku J. Exp. Med., 2005, 206, 31.